Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

Modern Pathology

Volumn 30, Issue 3, 2017, Pages 340-349

  Rehman, Jamaal A ^a   Han, Gang ^b   Carvajal Hausdorf, Daniel E ^a   Wasserman, Brad E ^a   Pelekanou, Vasiliki ^a   Mani, Nikita L ^a   McLaughlin, Joseph ^a   Schalper, Kurt A ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MALE; NON SMALL CELL LUNG CANCER; NONHUMAN; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TISSUE SECTION; LUNG TUMOR; METABOLISM; PATHOLOGY; REPRODUCIBILITY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; REPRODUCIBILITY OF RESULTS;

EID: 84994719242     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.186     Document Type: Article

References (15)

1. Teixido C, Karachaliou N, Gonzalez-Cao M, et al. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12: 87-95.
2. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015;372:2018-2028.
3. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer. N Engl J Med 2015;373:1627-1639.
4. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-programmed death-protein 1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-265.
5. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art J Thorac Oncol 2015;10: 985-989.
6. Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death-ligand 1 expression in multifocal lung cancer. Clin Cancer Res 2015;22: 2177-2182.
7. Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 2016;6:20090.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med 2015;373: 123-135.
9. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of programmed deathligand expression in non-small-cell lung cancer. JAMA Oncol 2016;2:46-54.
10. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-1327.
11. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-programmed deathligand 1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.
12. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced nonsquamous cell (non-SQ) non-small cell lung cancer (non-small cell lung cancer) in ASCO Annual Meeting. J Clin Oncol 2015;33 (suppl; abstr LBA109).
13. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (programmed death-ligand 1) antibody, in patients with non-small cell lung cancer (non-small cell lung cancer) in ASCO Annual Meeting. J Clin Oncol 2015;33 (suppl; abstr 8032).
14. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
15. Spira AI, Keunchil P, Mazieres J et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2 L/3 L non-small cell lung cancer (POPLAR) in ASCO Annual Meeting. J Clin Oncol 2015;33 (Suppl, abstr 8010).